Radiotherapy drug developer NeoRx has started phase III clinical trials of its skeletal targeted radiotherapy (STR) technology for the treatment of multiple myeloma. Patient enrollment has begun, and approximately 20 major cancer centers across the U.S. and Canada are expected to participate, according to the Seattle-based firm.
By AuntMinnie.com staff writersOctober 2, 2000
Related Reading
NeoRx adds to coffers with $19 million equity investment, April 25, 2000
NeoRx begins STR trials for Ewing’s Sarcoma, March 24, 2000
NeoRx gets research grant from NCI, February 21, 2000
Copyright © 2000 AuntMinnie.com